Orca Bio logo

Orca Bio

Emerging

Orca Bio is developing high-purity precision cell therapies using proprietary cell sorting technology to improve the safety and outcomes of bone marrow transplantation; raised $270M+; lead programs in AML, MDS, and other blood cancers;

Best for: Precision Cell Therapy for Cancer & Autoimmune DiseaseEmerging, rapid growth
Life Sciences & BioTechPrecision Cell Therapy for Cancer & Autoimmune DiseaseWebsiteUpdated May 2026

Company Overview

About Orca Bio

Orca Bio is a Menlo Park, California-based biotechnology company founded in 2016 that is developing next-generation cell therapies for blood cancers and autoimmune diseases through a proprietary high-precision cell sorting and manufacturing platform. The company's core technology enables the production of precisely defined cell therapy products — specifically, highly purified stem cell grafts and engineered immune cell compositions for allogeneic (donor-to-patient) bone marrow transplantation. Unlike conventional bone marrow transplants, which transfer a heterogeneous mixture of cells that can attack the patient's body (graft-versus-host disease, or GVHD), Orca Bio's manufactured grafts are composed of precisely selected cell populations that retain the anti-cancer effect while dramatically reducing the cells responsible for GVHD.

Business Model & Competitive Advantage

Orca Bio has raised over $270M from investors including New Enterprise Associates (NEA), Blackstone Life Sciences, Monashee Investment Management, and Foresite Capital. The company's lead clinical programs target acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) in patients undergoing allogeneic bone marrow transplantation. Phase 2 clinical data has demonstrated GVHD rates dramatically lower than historical benchmarks for conventional transplantation — a result that, if confirmed in registrational trials, would represent a major advance in the treatment of these life-threatening blood cancers. The company is advancing toward a Phase 3 pivotal trial and a potential BLA submission to the FDA.

Competitive Landscape 2025–2026

Orca Bio sits at the intersection of three of the most active areas in oncology: cell therapy (pioneered by CAR-T leaders like Bristol-Myers Squibb and Kite/Gilead), precision medicine (enabled by advances in single-cell biology), and transplant immunology. The company competes in the allogeneic cell therapy space alongside companies like Magenta Therapeutics (acquired), Vor Biopharma, and Editas Medicine in adjacent gene editing approaches, but Orca Bio's precision cell manufacturing platform represents a distinct technical approach that is further along clinically than most competitors working on next-generation transplant platforms. If approved, Orca Bio's product could become a standard of care for the tens of thousands of patients who receive allogeneic bone marrow transplants annually in the US.

Founded
2016
Headquarters
Orca Bio is a Menlo Park, California
Curated content • Fact-checked and verified

Key Differentiators

Emerging Innovator

Orca Bio is an emerging player bringing innovative solutions to the Life Sciences & BioTech market.

Frequently Asked Questions

Similar Brands

Illumina logo

Illumina

Life Sciences & BioTech
B2bGlobalPublicEnterpriseHealthtechAnalyticsHardwarePlatformFortune500

Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applicat

Pliant Therapeutics logo

Pliant Therapeutics

BioTech
HealthtechTechnologyPublicB2bStartup

Pliant Therapeutics develops small molecule integrin inhibitors targeting the pathological tissue scarring (fibrosis) that drives diseases including idiopathic pulmonary fibrosis (IPF), primary sclero

Cradle logo

Cradle

Life Sciences & BioTech
HealthtechSaasNorth AmericaB2b

Cradle is a protein design platform using AI to help biotechnology and pharmaceutical companies engineer better proteins — enzymes, antibodies, and therapeutic proteins — with improved stability, acti

Neuralink logo

Neuralink

Life Sciences & BioTech
HealthtechHardwareAi PoweredB2b2cStartupDecacornNorth AmericaTechnologyPlatformEnterprise

Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with pa

BioNTech logo

BioNTech

Life Sciences & BioTech
B2bGlobalPublicEnterpriseHealthtechManufacturingPlatform

BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneere

Genentech logo

Genentech

Life Sciences & BioTech
B2bGlobalEnterprisePublicHealthtechManufacturingFortune500

Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching

Compare Orca Bio with Competitors

Side-by-side AI visibility scores, platform breakdown, and market position.

For Orca Bio

Claim This Profile

Are you from Orca Bio? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.

Claim Orca Bio Profile →
For competitors & analysts

Track AI Visibility in Real Time

Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Orca Bio vs competitors. Get alerts when AI recommendations shift.

Start Free Tracking →